✦ LIBER ✦

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

✍ Scribed by Jacobs, B.; De Roock, W.; Piessevaux, H.; Van Oirbeek, R.; Biesmans, B.; De Schutter, J.; Fieuws, S.; Vandesompele, J.; Peeters, M.; Van Laethem, J.-L.; Humblet, Y.; Penault-Llorca, F.; De Hertogh, G.; Laurent-Puig, P.; Van Cutsem, E.; Tejpar, S.

Book ID: 119973299
Publisher: American Society of Clinical Oncology
Year: 2009
Tongue: English
Weight: 231 KB
Volume: 27
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2008.21.3744

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Amphiregulin and Epiregulin mRNA express

Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases

✍ Hidekazu Kuramochi; Go Nakajima; Yuka Kaneko; Ayako Nakamura; Yuji Inoue; Masaka 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 276 KB

P19 Levels of amphiregulin and epireguli

P19 Levels of amphiregulin and epiregulin expression correlate with overall survival in colorectal cancer treated with cetuximab

✍ W. De Roock; B. Biesmans; J. De Schutter; H. Piessevaux; E. Van Cutsem; S. Tejpa 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Gene expression of ferredoxin reductase

Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin

✍ Wataru Ichikawa; Akio Ooyama; Etsuko Toda; Yoshikazu Sugimoto; Toshinori Oka; Ta 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 317 KB

FCGR2AandFCGR3Apolymorphisms and clinica

FCGR2AandFCGR3Apolymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

✍ Kjersem, Janne B; Skovlund, Eva; Ikdahl, Tone; Guren, Tormod; Kersten, Christian 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 384 KB

6113 BRAF V600E mutation and Amphireguli

6113 BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients

✍ Cremolini, C.; Loupakis, F.; Perrone, G.; Ruzzo, A.; Rulli, E.; Bencardino, K.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

98 POSTER DUSP4 expression level in colo

98 POSTER DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease

✍ W. De Roock; M. Janssens; B. Biesmans; B. Jacobs; J. De Schutter; Y. Humblet; M. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB